Merck to acquire Acceleron Pharma
KENILWORTH, N.J. — Merck and Acceleron Pharma have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Acceleron for $180 per share in cash for an approximate total equity value of $11.5 billion, the companies said Thursday. Acceleron is focused on harnessing the power of the transforming growth factor (TGF)-beta superfamily